We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lantheus to Pay POINT Biopharma $260M for Two Late-Stage Cancer Treatments
Lantheus to Pay POINT Biopharma $260M for Two Late-Stage Cancer Treatments
Lantheus, which specializes in radiopharmaceutical diagnostic and therapeutic products, will pay $260 million in upfront license fees — with potential for another $1.8 billion — for worldwide rights to two of POINT Biopharma’s late-stage cancer therapeutic candidates.